Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study건강한 성인에서 이종 및 동종 불활성화 및 아데노바이러스 매개 COVID-19 백신 요법의 안전성 및 면역원성: 전향적 코호트 연구Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] Adults adverse event adverse events Antibody Response AstraZeneca ChAdOx1 ChAdOx1-S circulating variants combinations CoronaVac country COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Efficacy Evidence evidence of followed by group groups healthy Heterologous heterologous adenoviral vector heterologous vaccine homologous IgA response immune response immune responses immunized immunogenicity inactivated Inactivated vaccine interferon gamma Mild neutralizing activities Neutralizing activity prospective cohort study reactogenicity Receptor-binding domain referred to regimen Safety Serious Adverse Event Serious Adverse Events supply shortage vaccination Vaccine variants variants of concern Viral viral vectored. wild-type [DOI] 10.1080/21645515.2022.2029111 PMC 바로가기 [Article Type] Article
Concordance of SARS-CoV-2 Antibody Results during a Period of Low PrevalenceArticle Published on 2022-10-262022-11-15 Journal: mSphere [Category] COVID19(2023년), SARS, 진단, [키워드] 95% confidence interval Abbott acute respiratory syndrome Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG Antigen antigens Architect assays CDC collected combinations Concentration Concordance contributed coronavirus coronavirus disease COVID-19 Elecsy ELISA enzyme-linked immunosorbent evaluate False positivity first test Frequency IgG IgG antibodies immunoassay immunoassays Immunoglobulin individual investigated low prevalence nucleocapsid nucleocapsid protein pandemic participant Participants performed Period positive positive result Prevalence produced proportion quantified Research Result Roche SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 IgG antibody sequential test sera serological test seropositive specimen Spike protein spike protein. subset Support target tested the SARS-CoV-2 The United States Vaccine vaccine availability [DOI] 10.1128/msphere.00257-22 PMC 바로가기
Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimensArticle Published on 2022-10-032022-11-15 Journal: The Journal of Experimental Medicine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] analysis antibody binding affinity biochemical breadth Cell ChAdOx1 ChAdOx1 vaccine Combination combinations COVID-19 vaccination COVID-19 vaccine effort elicited epitope exhibited Immunity intervals magnitude maturation memory B memory B cell monoclonal antibody mRNA Neutralizing neutralizing antibody regimen regimens response resulting SARS-CoV-2 SARS-CoV-2 pandemic significant difference specificity vaccination Vaccine viral variant while Wuhan-Hu-1 [DOI] 10.1084/jem.20220826 PMC 바로가기
Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysisArticle Published on 2022-08-312022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] antibody Antiviral antiviral therapy clinical development Combination combinations conserved COVID-19 Critical Determining disparate effective eight eligible in vitro in vitro activity inactive interquartile range loss of activity measure median monoclonal monoclonal antibody Multidrug resistance Mutation neutralization omicron Omicron variant receptor-binding domains reduced reduction in Region reported review SARS-CoV-2 Spike protein spike protein. spike receptor-binding domain Standardization susceptibility the median the SARS-CoV-2 therapeutic treating COVID-19 variant variants wild-type [DOI] 10.1128/spectrum.00926-22 PMC 바로가기
Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens Research Published on 2022-08-112022-10-05 Journal: Nature Communications [Category] SARS, 치료기술, [키워드] analysis Antigen BNT162b2 CD4 T-cell CD8 T-cell Cellular immune response ChAdOx1-nCoV-19 Cohort Combination combinations Comparative COVID-19 vaccine FIVE healthy individuals Heterologous highest homologous humoral Immunity induce mRNA-1273 reactogenicity regimen regimens SARS-CoV-2 T-cell the vaccine vaccination Vaccination strategy Vaccine [DOI] 10.1038/s41467-022-32321-0 [Article Type] Research
Blood biomarkers representing maternal-fetal interface tissues used to predict early-and late-onset preeclampsia but not COVID-19 infectionResearch article Published on 2022-08-082022-10-05 Journal: Computational and Structural Biotechnology Journal [Category] 바이오마커, [키워드] Applying AUROC Biomarker Biomarkers Blood blood transcriptome change characteristic chose Cluster Co-infection collected combinations confidence interval COVID-19 COVID-19 infection COVID-19 pandemic dataset defined DEGs differentially expressed disorder dysfunction early-onset eligible endothelial event experiments explained expressed identify independent Infection information interferon Intervention IRF6 ITGA5 machine learning males mechanism MOST overlapped P2RX7 pandemic placental positive predict predicted Predictive predictor preeclampsia Pregnancy proportion Regulatory representing Result selected severe COVID-19 significantly tissue tissues transcript Transcriptome was determined with COVID-19 Z-score [DOI] 10.1016/j.csbj.2022.08.011 [Article Type] Research article
The Efficacy of Aprotinin Combinations with Selected Antiviral Drugs in Mouse Models of Influenza Pneumonia and Coronavirus Infection Caused by SARS-CoV-2SARS-CoV-2로 인한 인플루엔자 폐렴 및 코로나바이러스 감염의 마우스 모델에서 선택된 항바이러스제와 아프로티닌 조합의 효능Article Published on 2022-08-052022-09-11 Journal: Molecules [Category] SARS, 치료제, [키워드] Antiviral antiviral drugs Aprotinin body weight Body weight loss clinical assessment Combination combinations coronavirus COVID-19 demonstrated drug Efficacy Infection Influenza influenza pneumonia Influenza virus influenza. lung Lungs mice Model mouse preclinical study reducing SARS-CoV-2 selected survival rate treatment of influenza virus virus titer weight loss [DOI] 10.3390/molecules27154975 PMC 바로가기 [Article Type] Article
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in SingaporeArticle Published on 2022-08-012022-11-16 Journal: JAMA Network Open [Category] SARS, 변종, [키워드] 95% CI adjusted Against age Assessing BBIBP-CorV BNT162b2 booster cohort study Combination combinations CoronaVac COVID-19 COVID-19 vaccination death defined determine dose Effectiveness eligible Estimated greater homologous inactivated individual Infection intensive care Moderna mRNA mRNA COVID-19 vaccine mRNA vaccine mRNA-1273 no significant difference Older omicron outcome Pfizer-BioNTech provided reduction Reinfection SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 variant severe COVID-19 severe disease Sex Singapore Sinopharm Sinovac supplemental oxygen time interval vaccination Vaccine vaccine dose waned was determined were excluded women [DOI] 10.1001/jamanetworkopen.2022.28900 PMC 바로가기
Spread of endemic SARS-CoV-2 lineages in Russia before April 20212021년 4월 이전 러시아의 고유 SARS-CoV-2 계통 확산Article Published on 2022-07-202022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 변종, [키워드] Alpha B.1.1 B.1.1.7 B.1.351 Beta characterized Combination combinations country COVID-19 cases COVID-19 pandemic Deletion deletions delta variant Endemic Evidence Frequency highest hotspot identify indicate joint Lineage lineages Mutation mutations notable NSP6 ORF1a P.1 pandemic PCR testing remained Russia SARS-CoV-2 lineage spike glycoprotein Spread spring summer the epidemic Transmissibility variant variants variants of concern [DOI] 10.1371/journal.pone.0270717 PMC 바로가기 [Article Type] Article
Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies이종 saRNA 프라임, DNA 이중 항원 부스트 SARS-CoV-2 백신 접종으로 강력한 세포 면역원성과 교차 변형 중화 항체 유도Article Published on 2022-07-152022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] Adenovirus animal model animal models B.1.617.2 Beta boost CD4+ CD8+ T-cell combinations COVID-19 D614G mutation Delta distribution DNA dual dual antigen ENCODE enhanced expression followed by furin furin cleavage region Glutamine Heterologous highest homologous homologous or heterologous Humoral response humoral responses IgG immune response immune responses immunogenicity lipid carrier MHC class I MHC class I and II mice motif N antigen Neutralizing nucleic acid nucleocapsid omicron peptide peptides prefusion conformation prime proline prolines protease pseudovirus receiving regimen regimens Region response RNA vaccine SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant self-amplifying RNA sequence sera serotype spike Stimulation strain Strains Support T-cell T-cell responses vaccination Vaccine vaccine. Vaccines variant wild type Wuhan [DOI] 10.3389/fimmu.2022.910136 PMC 바로가기 [Article Type] Article